These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Novel 4-anilinoquinazolines with C-6 carbon-linked side chains: synthesis and structure-activity relationship of a series of potent, orally active, EGF receptor tyrosine kinase inhibitors. Hennequin LF; Ballard P; Boyle FT; Delouvrié B; Ellston RP; Halsall CT; Harris CS; Hudson K; Kendrew J; Pease JE; Ross HS; Smith P; Vincent JL Bioorg Med Chem Lett; 2006 May; 16(10):2672-6. PubMed ID: 16516473 [TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological evaluation of substituted 6-alkynyl-4-anilinoquinazoline derivatives as potent EGFR inhibitors. Liu LT; Yuan TT; Liu HH; Chen SF; Wu YT Bioorg Med Chem Lett; 2007 Nov; 17(22):6373-7. PubMed ID: 17889528 [TBL] [Abstract][Full Text] [Related]
12. Identification and optimisation of a series of substituted 5-(1H-pyrazol-3-yl)-thiophene-2-hydroxamic acids as potent histone deacetylase (HDAC) inhibitors. Price S; Bordogna W; Bull RJ; Clark DE; Crackett PH; Dyke HJ; Gill M; Harris NV; Gorski J; Lloyd J; Lockey PM; Mullett J; Roach AG; Roussel F; White AB Bioorg Med Chem Lett; 2007 Jan; 17(2):370-5. PubMed ID: 17095213 [TBL] [Abstract][Full Text] [Related]
13. Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. Klutchko SR; Zhou H; Winters RT; Tran TP; Bridges AJ; Althaus IW; Amato DM; Elliott WL; Ellis PA; Meade MA; Roberts BJ; Fry DW; Gonzales AJ; Harvey PJ; Nelson JM; Sherwood V; Han HK; Pace G; Smaill JB; Denny WA; Showalter HD J Med Chem; 2006 Feb; 49(4):1475-85. PubMed ID: 16480284 [TBL] [Abstract][Full Text] [Related]
14. Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Hennequin LF; Stokes ES; Thomas AP; Johnstone C; Plé PA; Ogilvie DJ; Dukes M; Wedge SR; Kendrew J; Curwen JO J Med Chem; 2002 Mar; 45(6):1300-12. PubMed ID: 11881999 [TBL] [Abstract][Full Text] [Related]
15. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities. Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571 [TBL] [Abstract][Full Text] [Related]
16. The discovery of highly selective erbB2 (Her2) inhibitors for the treatment of cancer. Lippa B; Kauffman GS; Arcari J; Kwan T; Chen J; Hungerford W; Bhattacharya S; Zhao X; Williams C; Xiao J; Pustilnik L; Su C; Moyer JD; Ma L; Campbell M; Steyn S Bioorg Med Chem Lett; 2007 Jun; 17(11):3081-6. PubMed ID: 17398092 [TBL] [Abstract][Full Text] [Related]
17. N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. Hennequin LF; Allen J; Breed J; Curwen J; Fennell M; Green TP; Lambert-van der Brempt C; Morgentin R; Norman RA; Olivier A; Otterbein L; Plé PA; Warin N; Costello G J Med Chem; 2006 Nov; 49(22):6465-88. PubMed ID: 17064066 [TBL] [Abstract][Full Text] [Related]
18. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor. Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862 [TBL] [Abstract][Full Text] [Related]
19. Cellular and in vivo activity of JNJ-28871063, a nonquinazoline pan-ErbB kinase inhibitor that crosses the blood-brain barrier and displays efficacy against intracranial tumors. Emanuel SL; Hughes TV; Adams M; Rugg CA; Fuentes-Pesquera A; Connolly PJ; Pandey N; Moreno-Mazza S; Butler J; Borowski V; Middleton SA; Gruninger RH; Story JR; Napier C; Hollister B; Greenberger LM Mol Pharmacol; 2008 Feb; 73(2):338-48. PubMed ID: 17975007 [TBL] [Abstract][Full Text] [Related]
20. Synthesis and biological evaluation of crown ether fused quinazoline analogues as potent EGFR inhibitors. Hu S; Xie G; Zhang DX; Davis C; Long W; Hu Y; Wang F; Kang X; Tan F; Ding L; Wang Y Bioorg Med Chem Lett; 2012 Oct; 22(19):6301-5. PubMed ID: 22959248 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]